Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher and Luminex.
The global flow cytometry market is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%.
The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services.Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics.
In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor.
The flow cytometry market covered in this report is segmented by type into instruments, reagents & consumables, software, accessories, services. It is also segmented by technology into cell-based, bead-based; by end user into hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, other end users and by application into oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, hematology.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market.These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay.
While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry.In ELISA, colour changes in reagents are used to detect problematic cells.
While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells.Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate.
However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput.
High-throughput flow cytometry is an emerging trend in the flow cytometry market.This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique.
Traditional cytometry methods are very slow, especially when several cells need to be tested within a day.Using high-throughput flow cytometry methods such as fluorescence-activated cell-sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time.
Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis.
In February 2019, Danaher acquired the biopharma business of GE Life Sciences for $21.4 billion. This acquisition will help Danaher to improve its existing bioprocessing capabilities. The biopharma division of GE Life Sciences is involved in the development and production of biologic drugs, vaccines and cell therapies. It develops products and solutions that facilitate research into fundamental cell and protein biology. GE Life Sciences is a division of GE Healthcare, which was founded in 1994 and has its headquarters in Illinois, the USA.
The increasing number of HIV cases globally is an important driver for the flow cytometry market.This is because the flow cytometry technique has its direct application in HIV diagnosis.
Flow cytometry uses light scattering to determine the identity of cells.These cells are given certain markers called CDs (clusters of differentiation), based on the type of scattering.
For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing.
The US FDA’s code of federal regulations (CFR) includes regulations related to a flow cytometry device called the automated differential cell counter (ADCC).An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts.
This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used.Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices.
Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the Precision Medicine partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Precision Medicine...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth...
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021 Summary According to the recently published report ’Insulin Like Growth Factor I - Drugs In Development, 2021’; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals. The global interleukin inhibitors market is expected to grow from $17.73 billion in 2020 to $19.88 billion in 2021 at a compound annual growth...
Global Academic and Non-Profit Partnering Terms and Agreements 2015 to 2021 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The Global Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies...
The Global Stem Cell Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering...
The global oxidative stress assay market reached a value of US$ 836 Million in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 9.7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.